Does Zyn Cause Cancer?

“Does Zyn cause cancer” is one of the most common searches about nicotine pouches, and the honest answer is that we do not know yet, for a specific reason: the studies that would answer it have not been completed. That is not a dodge. It is not a hedge dressed up as caution. It is the actual state of the evidence, and understanding why requires looking at how cancer risk is established in the first place and what kind of data nicotine pouches have generated so far.

Why the answer is genuinely uncertain

Long-term cancer risk is established through epidemiological cohort studies that follow large groups of people over many years, often decades. The studies that linked cigarettes to lung cancer took twenty to thirty years of accumulated data before the association became undeniable [3]. That is not because the risk was subtle; it was because cancer takes time to develop, and the statistical methods require large populations observed over long periods to separate a product’s effect from background cancer rates.

Nicotine pouches in their current form have been widely available in the US since roughly 2019. That is simply not enough time for the relevant data to exist. No researcher, no matter how well-funded or well-designed their study, can produce a twenty-year follow-up on a product that has been widely used for fewer than ten years. This is a constraint of time, not of effort or interest.

This means anyone who tells you pouches cause cancer is filling a gap with speculation. Anyone who tells you they do not cause cancer is filling the same gap from the other direction. The honest position is in between: the data does not yet extend far enough to answer the question, and the right thing to do is examine what evidence does exist and be clear about where it stops.

What we do know: TSNAs

Tobacco-specific nitrosamines are compounds formed during tobacco processing that are established carcinogens in both laboratory animals and human epidemiological studies [2]. They are the primary cancer-causing agents in smokeless tobacco products like chewing tobacco and snus. NNK and NNN, the two most studied TSNAs, have been shown to induce tumors in animal models at the sites relevant to human tobacco-related cancers: lung, oral cavity, esophagus, and pancreas. The International Agency for Research on Cancer classifies smokeless tobacco as a Group 1 carcinogen, partly on the basis of TSNA exposure [3].

Nicotine pouches contain TSNAs, but at substantially lower levels than traditional smokeless tobacco. An independent analysis at the University of Minnesota found detectable but low TSNA concentrations in US-market nicotine pouches [1]. The levels were orders of magnitude below those found in snus or moist snuff. This matters because the dose-response relationship for carcinogens is central to risk assessment: a lower exposure, all else being equal, means a lower risk, though “lower” and “zero” are different claims with different evidence requirements.

Whether these lower TSNA levels carry meaningful cancer risk over long-term use is one of the open questions that current data cannot answer. The levels are low enough that some toxicologists consider the incremental risk negligible compared to background cancer rates. Others point out that there is no established safe threshold for exposure to known carcinogens, and that characterizing a risk as negligible requires evidence that does not yet exist for this specific product and duration of use.

What we do know: no combustion

The other significant fact is what nicotine pouches do not do. They produce no smoke. Cigarette smoke contains over 7,000 chemicals, including at least 70 known carcinogens, the overwhelming majority of which are products of combustion rather than components of the tobacco itself [6]. The lung cancer, oral cancer, throat cancer, and bladder cancer risks associated with cigarettes are driven primarily by these combustion products, not by nicotine. By removing combustion entirely, nicotine pouches remove the mechanism responsible for the majority of tobacco-related cancer.

This is the basis for the harm-reduction argument, and it is well-grounded in the underlying science. The Royal College of Physicians concluded in their 2016 independent review that non-combustible nicotine products are likely to carry a small fraction of the risk of cigarettes [6]. That conclusion rests on decades of research into what makes cigarettes harmful, and the answer is overwhelmingly the combustion process and its chemical byproducts.

For the cancer question specifically, this means the dominant mechanism is absent. The carcinogens that drive lung cancer, the leading cause of smoking-related death, are not present in a product that produces no smoke. The oral and throat carcinogens generated by smoke and heat exposure are not present either. What remains is the low-level TSNA exposure, the nicotine itself, and the other compounds in the pouch formulation.

Nicotine’s role in cancer

Nicotine is not classified as a carcinogen by the IARC or by any major regulatory body. It does not directly cause the DNA mutations that initiate cancer. However, laboratory studies have suggested that nicotine may have tumor-promoting effects: it can stimulate angiogenesis, the growth of new blood vessels that tumors need to expand, and it may interfere with apoptosis, the process by which the body eliminates abnormal cells [2].

Whether these laboratory effects translate to meaningful cancer promotion at the nicotine concentrations delivered by pouches in humans is unknown. The distinction between a substance that can promote tumor growth in a cell culture and one that measurably increases cancer risk in a living person using a consumer product is large. Many substances show effects in the lab that do not materialize at real-world exposure levels. But the uncertainty is real, and the honest answer is that nicotine’s role in cancer promotion at the doses involved in pouch use has not been established or ruled out.

The snus comparison

The closest long-term data we have comes from Swedish snus, a moist tobacco product that has been used in Scandinavia for decades. This is the only oral nicotine product with enough population-level exposure time to support cohort studies of the kind needed to assess cancer risk.

Meta-analyses of Scandinavian cohort data generally do not find an elevated overall cancer risk for snus users, though some individual studies suggest a possible association with pancreatic cancer [4]. The overall cancer picture for snus is vastly better than for cigarettes, which is consistent with the removal of combustion. Sweden, which has the highest snus use rate in Europe and the lowest male smoking rate, also has the lowest male lung cancer rate on the continent.

Snus is not a direct comparison for modern nicotine pouches. It contains actual tobacco leaf, has higher TSNA levels, and has a different chemical profile. Nicotine pouches, particularly synthetic-nicotine variants, may have an even more favorable toxicant profile than snus. But the snus data provides the strongest available evidence that oral nicotine use without combustion does not produce cancer rates anywhere near those associated with smoking. It is the best surrogate data we have while the pouch-specific studies accumulate.

The practical position

The question has a real answer; it is just not a satisfying one for anyone looking for a clean yes or no. We do not know if nicotine pouches cause cancer over decades because the product has not been around for decades. The short-term toxicant data is encouraging: lower TSNA levels than any other nicotine product with tobacco-derived ingredients, no combustion products, biomarker profiles that approach those of non-users in the switching studies available [5]. The biomarker study was funded by Swedish Match, which is a calibration factor, not a disqualifier. The biomarker methodology is standard, and the magnitude of the reductions is consistent with what the toxicology would predict.

The absence of combustion removes the dominant cancer mechanism. The low TSNA levels reduce, but do not eliminate, the residual concern. Nicotine’s potential tumor-promoting effects are a theoretical risk that laboratory work has not resolved at real-world exposure levels. Each of these facts points in the same direction: the cancer risk of nicotine pouches is almost certainly much lower than that of cigarettes, and it may be very low in absolute terms. But “may be very low” is not the same as “is zero,” and filling that gap requires time and data that do not yet exist.

What remains unknown

Whether long-term use of nicotine pouches at current TSNA levels carries any detectable cancer risk above background rates. Whether nicotine at the concentrations delivered by pouches promotes tumor growth in humans in a clinically meaningful way. Whether the pH adjusters, flavorings, and filler materials in pouches have any long-term effects on oral tissue that could contribute to cancer risk. Whether the answer differs for different usage patterns, such as the person who uses two pouches a day versus the person who uses a tin a day for twenty years.

Each of these questions requires data that does not yet exist, and no amount of certainty in either direction, from industry representatives or from health advocates, makes that data appear. The studies will take time. The honest answer, uncomfortable as it may be, is the only accurate one available.

If you have questions about nicotine use and your health, speak with a doctor or pharmacist. The Quitline (1-800-QUIT-NOW) can help with quitting strategies.